It is now our standard of care to offer an Internet blood glucose monitoring system to patients. We currently have 1,100 patients enrolled and have outcome data on the first 409 patients. Of the 409 patients, 388 had HbA 1c at baseline and at least one subsequent HbA 1c determination within 9 months. HbA 1c values from 3-9 months were averaged to generate follow-up data. The relationship of reporting frequency and HbA 1c change was determined by dividing patients into frequent reporters, who reported more than once per month, and infrequent reporters.
Patients were instructed to upload selfmonitoring of blood glucose readings every 2 weeks through their choice of platform including CareLink (Medtronic), meters equipped with report-generating software (Contour USB, Bayer; FreeStyle InsuLinx, Abbott; iBGStar, Sanofi), and a customized spreadsheet (Excel, Microsoft). All platforms generated reports presenting the mean, SD, and range of glucose values according to time of day. The patient's endocrinologist reviewed the readings and sent feedback to the patient via e-mail. Recommendations included changes in therapy, testing frequency, and lifestyle or encouragement to continue with no changes.
Key results are summarized in Table 1 .
HbA 1c in all type 2 diabetic patients declined from 8.36 6 1.35% to 7.91 6 0.98% (P , 0.001). For type 2 diabetic patients treated with insulin, HbA 1c declined from 8.53 6 0.82 to 8.12 6 0.91% (P , 0.001). Type 2 diabetic patients exclusively on oral hypoglycemic agents (OHAs) declined from 8.15 6 0.98 to 7.67 6 1.29% (P , 0.001).
At baseline for type 2 diabetic patients, there was no statistically significant difference in HbA 1c values for the groups whether they were frequent or infrequent reporters. At follow-up, it was found that HbA 1c in frequent reporters were significantly lower than in infrequent reporters, regardless of treatment (P , 0.05).
It was found that type 1 diabetic patients who had "ideal" HbA 1c showed little decrement in HbA 1c values. When excluding patients with HbA 1c ,6.9 (n 5 17), type 1 diabetic patients showed a decline of 8.12 6 1.38% to 7.93 6 1.17% (P , 0.01).
We observed a trend of less frequent reporting among type 1 diabetic patients with lower HbA 1c values. When we excluded patients with HbA 1c ,7.4 (n 5 26), we found frequent reporters had lower follow-up HbA 1c than infrequent reporters (P , 0.05).
Regardless of type of diabetes or treatment, all patients improved significantly. Additionally, when separated into frequent versus infrequent reporters, we found no differences at baseline. At follow-up, frequent reporters had consistently lower HbA 1c values.
Previously, there has been a lack of data to fully demonstrate the efficacy of Internet interventions on type 1 diabetic patients, with most available studies conducted on much smaller sample sizes (4,5). We found Internet intervention to be effective across all groups, including type 1 diabetic patients. The lowering of HbA 1c improves long-term diabetes outcome and lowers costs. The efficacy of this intervention warrants consideration of coverage for this service by insurance plans. 
